Speciality Medicines Ltd.
SMEBSE₹117–124
₹ 29 Cr
2000 Shares
₹ 2,34,000
₹10
Financial Summary
| Particulars | FY 2022-23 |
|---|---|
| 2,317.5 | |
| 2.4 | |
| 2,319.9 | |
| 1,958.5 | |
| 295.57 | |
| 169.61 |
Subscription Details
Subscription
IPO Timeline
IPO Offer Start
20 Mar 2026
IPO Offer Ends
24 Mar 2026
30 Mar 2026
Use of Proceeds
| # | Purpose | Amount (₹ Million) |
|---|---|---|
| 1 | Setting up of Research and Development (R&D) Center | 126.764 |
| 2 | Product registration in the international markets and Product Development for sale | 29.925 |
| 3 | Funding for Marketing and Promotional Activities | 16.561 |
| 4 | To Meet Working Capital Requirements | 80 |
| 5 | General Corporate Purposes | 2.5 |
Promoters
Book Running Lead Managers
Promoter Shareholding
Pre-IPO
62.16%
Promoter stake
Post-IPO
43.43%
Promoter stake
Offered to Public
23,50,000
shares
Post Share Capital
38,15,500
shares
About the Company
Our company is engaged in marketing & distribution of finished formulations of Specialty pharmaceuticals - high-cost oral or injectable medications used to treat complex chronic conditions in Domestic as well as International Market. Having cultivated strong and dependable customer relationships in Specialty pharmaceuticals, we have, through our distributions, established good repo with our customers spreading across more than 20 states of India and more than 35 countries all over the worlds. Our mission is to enhance patient care by supplying high-quality, innovative medicines that address unmet medical needs. With a strong commitment to excellence, we aim to make a positive impact on the lives of patients worldwide.
Use of Proceeds
1. Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje: Manda, Tal. Umargam, Dist. Valsad, Gujarat; 2. Product Registration in International Markets and Product Development for sale in international markets. 3. Funding for Marketing and Promotional Activities. 4. To Meet Working Capital Requirements; and 5. General Corporate Purpose.
Speciality Medicines Ltd. Latest News
News
Speciality Medicines gets regulatory approval for two new products in Ethiopia
With these approvals, the company's total registered product portfolio in the Ethiopian market stands at 12 formulations
Speciality Medicines informs about disclosure
Speciality Medicines coming with IPO to raise up to Rs 29.14 crore
The issue will open on March 20, 2026 and will close on March 24, 2026